Nab‐paclitaxel in older patients with non–small cell lung cancer who have developed disease progression after platinum‐based doublet chemotherapy

摘要: Background The selection of later-line treatment for older patients with AJCC (version 7) stage IV non-small cell lung cancer (NSCLC) remains controversial. Nanoparticle albumin-bound (nab)-paclitaxel is approved carboplatin the first-line NSCLC and subgroup analysis phase 3 data has suggested superior survival in patients. Methods authors conducted a 2 study nab-paclitaxel 42 aged ≥70 years who had been treated previously platinum doublet regimen; also could have received PD-1 inhibitor. primary endpoint current was grade to 5 toxicity (according National Cancer Institute Common Terminology Criteria Adverse Events [version 4.0]). In addition response rate, progression-free (PFS), overall (OS), geriatric assessments were performed before during treatment, associations between baseline sarcopenia outcomes explored, changes T lymphocyte p16 measured. retrospective 19 as part larger, randomized, study; not combined. Results rate toxicities 33.7%. most common decreased white blood count (11.9%), neutropenia (9.5%), fatigue (11.9%). 34.2% (2.6% complete 31.6% partial rate). median PFS 5.2 months OS 9.3 months. prognostic factors common: 42% frail 39% prefrail, whereas 21% an Eastern Cooperative Oncology Group performance status 27% sarcopenic. Only frailty found be predictive inferior survival. A alone prior trial demonstrated 15.8%, 4.2 months, 13.6 Conclusions Fit prefrail should considered after disease progression chemotherapy.